REGENERON PHARMACEUTICALS, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
REGENERON PHARMACEUTICALS, INC. (REGN) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $120.62 million for the 12-month period ending 2011-12-31, per its 10-K filed 2014-02-13.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2015-02-12
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2011 was $120.62M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 1 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 1 month as first filed | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|
| 2011-12-31 | $120.62M 10-K · filed 2014-02-13 | ||
| 2011-10-31 | $120.60M 10-K · filed 2015-02-12 | $120.62M 10-K · filed 2012-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |